NeuroMetrix, Inc. announced the commercial availability of DPNCheck 2.0, the Company's latest point-of-care device that leverages gold-standard nerve conduction technology to detect peripheral neuropathy. DPNCheck 2.0 provides rapid patient screening with quantitative measurement of peripheral nerve function. It features an easy-to-use touchscreen, onboard step-by-step instructions, improved temperature compensation, real-time nerve response display and other enhancements.

Its companion software facilitates clinical documentation of test results. Cloud-based aggregation of population-health data and integration with provider EHR systems is planned for later this year. Peripheral neuropathy, the systemic degeneration of peripheral nerves, is a common and debilitating condition that may affect up to 30% of the Medicare-aged population.

An increasing number of healthcare providers and health plans that support the Medicare population have recently turned their attention to early detection and management of this condition to help reduce their patientsÆ risk of foot ulcers, falls, pain and other complications. By incorporating screening for peripheral neuropathy using nerve conduction technology, it is possible to uncover elevated risk for these complications earlier and more accurately than traditional clinical approaches such as the monofilament and tuning fork tests. DPNCheck 2.0 will be presented at the Medicare Advantage Leadership Innovations National Conference January 24-25, 2023 at the Renaissance Glendale, AZ.

Please visit Neurometrix booth #21 to see the device in action and learn more from NeuroMetrixÆs value-based care and population health experts.